U.S. FDA Oncologic Drugs Advisory Committee Votes in Favor of the Benefit-risk Profile of Darzalex Faspro for High-risk Smoldering Multiple Myeloma
May 20, 2025
May 20, 2025
RARITAN, New Jersey, May 20 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit i . . .
* * *
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit i . . .